Evidence map›Paper›PMID 30096306›Full record

ArticleCell2018

Viral Teamwork Pushes CRISPR to the Breaking Point.

Philip M Nussenzweig, Luciano A Marraffini

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Isolation and Characterization ofFrontiers in microbiology · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Philip M NussenzweigLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Luciano A MarraffiniLaboratory of Bacteriology, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA. Electronic address: marraffini@rockefeller.edu.

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

Viruses have evolved inhibitors to counteract the CRISPR immune response, but they are not fully potent and need some time to be expressed after the beginning of infection. In this issue of Cell, Borges et al. and Landsberger et al. show that sequential infection gradually immunosuppresses the host to allow effective CRISPR inhibition.

Indexed as

BacteriophagesClustered Regularly Interspaced Short Palindromic RepeatsViruses

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.